COVID-19 치료제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The COVID-19 Therapeutics Market size is expected to reach USD 54.69 Billion in 2034 from USD 26.84 Billion (2025) growing at a CAGR of 8.23% during 2026-2034.

The COVID-19 Therapeutics Market is experiencing unprecedented growth as the global healthcare community continues to respond to the ongoing pandemic. Therapeutics for COVID-19 include antiviral medications, monoclonal antibodies, and supportive care treatments aimed at managing symptoms and reducing the severity of the disease. The urgent need for effective treatments to combat COVID-19 is driving significant investments in research and development, further propelling market expansion.

Technological advancements are playing a crucial role in shaping the future of the COVID-19 therapeutics market. Innovations in drug discovery and development processes, including the use of artificial intelligence and machine learning, are accelerating the identification of potential therapeutic candidates. Additionally, advancements in clinical trial methodologies, such as adaptive trial designs, are enhancing the efficiency of evaluating new treatments. As pharmaceutical companies and research institutions continue to collaborate and share data, the COVID-19 therapeutics market is likely to see rapid advancements and increased availability of effective treatment options.

Moreover, the growing emphasis on global health security and preparedness is influencing the COVID-19 therapeutics market's growth trajectory. As governments and health organizations recognize the importance of being equipped to handle future pandemics, there is a rising demand for therapeutics that can be rapidly deployed in response to emerging infectious diseases. This trend is driving collaboration between public and private sectors to develop robust supply chains and distribution networks for COVID-19 therapeutics. As the market continues to evolve, the integration of technology, global collaboration, and preparedness strategies will be key drivers of success.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Antiviral Drugs
• Immune Modulators
• Corticosteroids
• Monoclonal Antibodies
• Others

By Route Of Administration

• Oral
• Intravenous
• Others

By Distribution Channel

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Patient Demographics

• Pediatric
• Adult
• Geriatric

COMPANIES PROFILED

• Pfizer Inc, Moderna Inc, Gilead Sciences Inc, Regeneron Pharmaceuticals Inc, Eli Lilly and Company, Johnson Johnson, AstraZeneca PLC, BioNTech SE, GlaxoSmithKline plc, Sanofi SA, Roche Holding AG, Merck Co Inc, Novartis AG, AbbVie Inc, BristolMyers Squibb Company

We can customise the report as per your requriements

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL COVID-19 THERAPEUTICS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Antiviral Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Immune Modulators Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Corticosteroids Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Monoclonal Antibodies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL COVID-19 THERAPEUTICS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Intravenous Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL COVID-19 THERAPEUTICS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospitals Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL COVID-19 THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Patient Demographics
• 7.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Geriatric Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL COVID-19 THERAPEUTICS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Type
  • 8.2.2 By Route Of Administration
  • 8.2.3 By Distribution Channel
  • 8.2.4 By Patient Demographics
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Type
  • 8.3.2 By Route Of Administration
  • 8.3.3 By Distribution Channel
  • 8.3.4 By Patient Demographics
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Type
  • 8.4.2 By Route Of Administration
  • 8.4.3 By Distribution Channel
  • 8.4.4 By Patient Demographics
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Type
  • 8.5.2 By Route Of Administration
  • 8.5.3 By Distribution Channel
  • 8.5.4 By Patient Demographics
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Type
  • 8.6.2 By Route Of Administration
  • 8.6.3 By Distribution Channel
  • 8.6.4 By Patient Demographics
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL COVID-19 THERAPEUTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Pfizer Inc
  • 10.2.2 Moderna Inc
  • 10.2.3 Gilead Sciences Inc
  • 10.2.4 Regeneron Pharmaceuticals Inc
  • 10.2.5 Eli Lilly And Company
  • 10.2.6 Johnson & Johnson
  • 10.2.7 AstraZeneca PLC
  • 10.2.8 BioNTech SE
  • 10.2.9 GlaxoSmithKline Plc
  • 10.2.10 Sanofi S.A
  • 10.2.11 Roche Holding AG
  • 10.2.12 Merck & Co. Inc
  • 10.2.13 Novartis AG
  • 10.2.14 AbbVie Inc
  • 10.2.15 Bristol-Myers Squibb Company